Luye Pharma Group Ltd (2186):企業の財務・戦略的SWOT分析

◆英語タイトル:Luye Pharma Group Ltd (2186) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH222570FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥64,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥97,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Luye Pharma Group Ltd (Luye Pharma), a subsidiary of Luye Life Sciences Group Ltd is a drug development company that discovers, manufactures, and commercializes novel formulations, generic drugs, and pharmaceutical products. The company offers its products in the form of tablets, formulations for injections, capsules, gels, anti-psychotic medicines, and modified-release dosages in the therapeutic areas of endocrinology, oncology, cardiovascular, orthopedics, hepatology, gastroenterology, gynecology, diabetes and central nervous system (CNS). Luye Pharma operates its R&D and manufacturing facilities in the US, China and Europe. The company works in collaboration with Excel Biopharm, Abpro Corp and ELPIS Biopharm for developing cell therapies, nucleic acid therapeutics, and antibodies for immuno-oncology treatments. Luye Pharma is headquartered in Yantai, Shandong, China.

Luye Pharma Group Ltd Key Recent Developments

Mar 27,2021: Rykindo® Launched! First Innovative Microsphere Formulation Independently Developed in China Brings Increased Clinical Benefits to Schizophrenia Patients through World-leading Microsphere Technology
Mar 18,2021: Luye Pharma Starts Patient Enrollment in Phase I Clinical Trials for Its Investigational Analgesic Drug LY03014
Aug 27,2020: Luye Pharma: Announcement of interim results for the six months ended 30 June
Apr 23,2020: Luye Pharma Group selects LifeSphere Signal and Risk Management to automate drug safety signal detection
Mar 27,2020: Luye Pharma continues to deliver strong growth in 2019

This comprehensive SWOT profile of Luye Pharma Group Ltd provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Luye Pharma Group Ltd including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Luye Pharma Group Ltd – Key Information
Luye Pharma Group Ltd – Overview
Luye Pharma Group Ltd – Key Employees
Luye Pharma Group Ltd – Key Employee Biographies
Luye Pharma Group Ltd – Key Operational Heads
Luye Pharma Group Ltd – Major Products and Services
Luye Pharma Group Ltd – History
Luye Pharma Group Ltd – Company Statement
Luye Pharma Group Ltd – Locations And Subsidiaries
Luye Pharma Group Ltd
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Luye Pharma Group Ltd – Business Description
Luye Pharma Group Ltd – Corporate Strategy
Luye Pharma Group Ltd – SWOT Analysis
SWOT Analysis – Overview
Luye Pharma Group Ltd – Strengths
Luye Pharma Group Ltd – Weaknesses
Luye Pharma Group Ltd – Opportunities
Luye Pharma Group Ltd – Threats
Luye Pharma Group Ltd – Key Competitors

Section 3 – Company Financial Performance Charts

Luye Pharma Group Ltd – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Luye Pharma Group Ltd, Key Information
Luye Pharma Group Ltd, Key Ratios
Luye Pharma Group Ltd, Share Data
Luye Pharma Group Ltd, Major Products and Services
Luye Pharma Group Ltd, History
Luye Pharma Group Ltd, Key Employees
Luye Pharma Group Ltd, Key Employee Biographies
Luye Pharma Group Ltd, Key Operational Heads
Luye Pharma Group Ltd, Other Locations
Luye Pharma Group Ltd, Subsidiaries
Luye Pharma Group Ltd, Key Competitors
Luye Pharma Group Ltd, SWOT Analysis
Luye Pharma Group Ltd, Ratios based on current share price
Luye Pharma Group Ltd, Annual Ratios
Luye Pharma Group Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Luye Pharma Group Ltd (2186):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • FLSmidth & Co. A/S:企業の戦略・SWOT・財務分析
    FLSmidth & Co. A/S - Strategy, SWOT and Corporate Finance Report Summary FLSmidth & Co. A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Genera Biosystems Ltd (GBI):製品パイプライン分析
    Summary Genera Biosystems Ltd (GBL) is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pat …
  • EnergySolutions, Inc.:企業の戦略・SWOT・財務情報
    EnergySolutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary EnergySolutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Nerviano Medical Sciences Srl:製薬・医療:M&Aディール及び事業提携情報
    Summary Nerviano Medical Sciences Srl (NMS) is a drug development company that discovers and develops novel anticancer drugs. The company's pipeline products include anticancer compounds such as Danusertib, Encorafenib, Entrectinib, ADC Payload programs, PARP1 program, NMS-088, Brostallicin, Milcicl …
  • Triple Energy Ltd (TNP):石油・ガス:M&Aディール及び事業提携情報
    Summary Triple Energy Ltd (Triple Energy) is an oil and gas company that explores for natural resources. The company invests in oil and gas projects in the conventional and unconventional sectors such as coal seam gas and shale oil and gas, along with power generation. It offers project such as CFT …
  • Bill & Melinda Gates Foundation:企業のM&A・事業提携・投資動向
    Bill & Melinda Gates Foundation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bill & Melinda Gates Foundation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Infineon Technologies AG (IFX):企業の財務・戦略的SWOT分析
    Infineon Technologies AG (IFX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Sanford Health-製薬・医療分野:企業M&A・提携分析
    Summary Sanford Health (Sanford) is a healthcare service provider that offers medical services. The center’s medical services include allergy and immunology, acupuncture, adult trauma, airmed, anesthesiology, breast health, behavioral health, pediatric care, bladder health, bleeding disorders, botox …
  • Anglo Pacific Group plc:企業のM&A・事業提携・投資動向
    Anglo Pacific Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Anglo Pacific Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Future Fund:企業の戦略的SWOT分析
    Future Fund - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Kowa Co Ltd (7807):企業の財務・戦略的SWOT分析
    Kowa Co Ltd (7807) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Tarsa Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tarsa Therapeutics Inc (Tarsa) is a developer of therapies for the treatment and prevention of osteoporosis and other bone related diseases. The company develops calcitonin tablet TBRIA, an oral formulation of calcitonin, a peptide hormone that inhibits bone resorption, which is used for the …
  • President Energy PLC (PPC):石油・ガス:M&Aディール及び事業提携情報
    Summary President Energy PLC (President) is an independent oil and gas exploration and production company. It focuses mainly on Argentina and Paraguay in South America. The company has a diverse portfolio of operated onshore producing and exploration assets. Its major assets include working interest …
  • Minnkota Power Cooperative Inc:発電所・企業SWOT分析
    Minnkota Power Cooperative Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on ke …
  • Nord Gold SE:企業の戦略・SWOT・財務分析
    Nord Gold SE - Strategy, SWOT and Corporate Finance Report Summary Nord Gold SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Central Alabama Electric Cooperative Inc:企業の戦略的SWOT分析
    Central Alabama Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • ChanTest Corp-製薬・医療分野:企業M&A・提携分析
    Summary ChanTest Corp (ChanTest), a subsidiary of Charles River Laboratories International Inc is a contract research organization that discovers and develops drugs in ion channel and GPCR biology fields. The organization's ion channel products include cell lines and antibodies. Its other products c …
  • NeuroPace Inc-医療機器分野:企業M&A・提携分析
    Summary NeuroPace Inc (NeuroPace) is a medical device company that designs, develops, manufactures, and markets implantable devices for the treatment of neurological disorders. The company’s products include cutting edge medical devices, RNS systems, patient data management systems, magnet products, …
  • Latvenergo AS-エネルギー分野:企業M&A・提携分析
    Summary Latvenergo AS (Latvenergo) is a state-owned power supply utility company that generates and supplies electricity and thermal energy, distributes electricity, leases transmission system assets. It generates electricity through various renewable energy sources such as hydropower, biomass, wind …
  • PHX Energy Services Corp (PHX):企業の財務・戦略的SWOT分析
    Summary PHX Energy Services Corp (PHX Energy), formerly Phoenix Technology Income Fund is an energy service company that manufactures, designs, and engineers directional drilling technologies. The corporation’s equipment includes RADD, P-360 MWD, 360-CV MWD, E-360 MWD, 360 RWD, and performance motor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆